The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP
Open accessAbstract
Abstract The sodium taurocholate co-transporting polypeptide (NTCP,SLC10A1) is the main hepatic transporter of conjugated bile acids, and the entry receptor for hepatitis B virus (HBV) and hepatitis delta virus (HDV). Myrcludex B, a synthetic peptide mimicking the NTCP-binding domain of HBV, effectively blocks HBV and HDV infection. In addition, Myrcludex B inhibits NTCP-mediated bile acid uptake, suggesting that also other NTCP inhibitors could potentially be a novel treatment of HBV/HDV infection. This study aims to identify clinically-applied compounds intervening with NTCP-mediated bile acid transport and HBV/HDV infection. 1280 FDA/EMA-approved drugs were screened to identify compounds that reduce uptake of taurocholic acid and lower Myrcludex B-binding in U2OS cells stably expressing human NTCP. HBV/HDV viral entry inhibition was studied in HepaRG cells. The four most potent inhibitors of human NTCP were rosiglitazone (IC505.1 µM), zafirlukast (IC506.5 µM), TRIAC (IC506.9 µM), and sulfasalazine (IC509.6 µM). Chicago sky blue 6B (IC507.1 µM) inhibited both NTCP and ASBT, a distinct though related bile acid transporter. Rosiglitazone, zafirlukast, TRIAC, sulfasalazine, and chicago sky blue 6B reduced HBV/HDV infection in HepaRG cells in a dose-dependent manner. Five out of 1280 clinically approved drugs were identified that inhibit NTCP-mediated bile acid uptake and HBV/HDV infectionin vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several drugs such as rosiglitazone, zafirlukast and sulfasalazine inhibit NTCP.
“Moreover, several drugs such as rosiglitazone, zafirlukast and sulfasalazine inhibit NTCP.205”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [205]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, X., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,178
Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,484
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Seyec, J. L., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., TREPO, C. G., & Guguen‐Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,288
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Ilastik: Interactive learning and segmentation toolkit
Sommer, C., Straehle, C., Köthe, U., & Hamprecht, F. A. (2011) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi.2011.5872394 · Cited by 1,145
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Ni, Y., Lempp, F. A., Mehrle, S., Nkongolo, S., Kaufman, C., Fälth, M., Stindt, J., Königer, C., Nassal, M., Kubitz, R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.12.024 · Cited by 807
Dawson, P. A., Lan, T., & Rao, A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900012-jlr200 · Cited by 683
Ladner, S. K., Otto, M. J., Barker, C. S., Zaifert, K., Wang, G. H., Guo, J., Seeger, C., & King, R. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1715 · Cited by 644
Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 610
Celaya, F. B. (1989) · PubMed · Cited by 508
Kuo, M. Y., Chao, M., & Taylor, J. M. (1989) · Journal of Virology · doi:10.1128/jvi.63.5.1945-1950.1989 · Cited by 451
Bogomolov, P., Alexandrov, A., Воронкова, Н. В., Владиславовна, М. М., Kokina, K. Y., Petrachenkova, M., Lehr, T., Lempp, F. A., Wedemeyer, H. H., Haag, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.016 · Cited by 403
Improved Statistical Methods for Hit Selection in High-Throughput Screening
Brideau, C., Gunter, B., Pikounis, B., & Liaw, A. I. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103258285 · Cited by 337
Craddock, A. L., Love, M. W., Daniel, R. W., Kirby, L. C., Walters, H. C., Wong, M. H., & Dawson, P. A. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.274.1.g157 · Cited by 308
Nkongolo, S., Ni, Y., Lempp, F. A., Kaufman, C., Lindner, T., Esser‐Nobis, K., Lohmann, V., Mier, W., Mehrle, S., & Urban, S. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.022 · Cited by 257
Schulze, A., Schieck, A., Ni, Y., Mier, W., & Urban, S. (2009) · Journal of Virology · doi:10.1128/jvi.01902-09 · Cited by 238
Lütgehetmann, M., Mancke, L. V., Volz, T., Helbig, M., Allweiss, L., Bornscheuer, T., Pollok, J. M., Lohse, A. W., Petersen, J., Urban, S., et al. (2011) · Hepatology · doi:10.1002/hep.24758 · Cited by 229
Blank, A., Markert, C., Hohmann, N., Carls, A., Mikus, G., Lehr, T., Alexandrov, A., Haag, M., Schwab, M. G., Urban, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.013 · Cited by 221
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3
Walters, H. C., Craddock, A. L., Fusegawa, H., Willingham, M. C., & Dawson, P. A. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.279.6.g1188 · Cited by 180
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options
Lempp, F. A., Ni, Y., & Urban, S. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.126 · Cited by 164
Oehler, N., Volz, T., Bhadra, O. D., Kah, J., Allweiss, L., Giersch, K., Bierwolf, J., Riecken, K., Pollok, J. M., Lohse, A. W., et al. (2014) · Hepatology · doi:10.1002/hep.27159 · Cited by 162
Leslie, E. M., Watkins, P. B., Kim, R. B., & Brouwer, K. L. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.119073 · Cited by 137
Meier, A., Mehrle, S., Weiß, T. S., Mier, W., & Urban, S. (2012) · Hepatology · doi:10.1002/hep.26181 · Cited by 136
Structure-Based Identification of OATP1B1/3 Inhibitors
Bruyn, T. D., van Westen, G. J. P., IJzerman, A. P., Stieger, B., de Witte, P. A. M., Augustijns, P., & Annaert, P. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084152 · Cited by 131
Shimura, S., Watashi, K., Fukano, K., Peel, M. R., Sluder, A. E., Kawai, F., Iwamoto, M., Tsukuda, S., Takeuchi, J. S., Miyake, T., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.009 · Cited by 130
Li, W., & Urban, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.011 · Cited by 125
Kramer, W., Stengelin, S., Baringhaus, K. H., Enhsen, A., Heuer, H., Becker, W., Corsiero, D., Girbig, F., Noll, R., & Weyland, C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33406-4 · Cited by 116
Dilger, K., Hohenester, S. D., Winkler–Budenhofer, U., Bastiaansen, B. A. J., Schaap, F. G., Rust, C., & Beuers, U. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.014 · Cited by 113
Schieck, A., Schulze, A., Gähler, C., Müller, T. H., Haberkorn, U., Alexandrov, A., Urban, S., & Mier, W. (2013) · Hepatology · doi:10.1002/hep.26211 · Cited by 109
Dong, Z., Ekins, S., & Polli, J. E. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300453k · Cited by 104
Kaneko, M., Watashi, K., Kamisuki, S., Matsunaga, H., Iwamoto, M., Kawai, F., Ohashi, H., Tsukuda, S., Shimura, S., Suzuki, R., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01855-15 · Cited by 104
An Update on Hdv: Virology, Pathogenesis and Treatment
Alvarado-Mora, M. V., LOCARNINI, S. A., Rizzetto, M., & Pinho, J. R. R. (2005) · Antiviral Therapy · doi:10.3851/imp2598 · Cited by 94
Tsukuda, S., Watashi, K., Hojima, T., Isogawa, M., Iwamoto, M., Omagari, K., Suzuki, R., Aizaki, H., Kojima, S., Sugiyama, M., et al. (2016) · Hepatology · doi:10.1002/hep.28952 · Cited by 81
Taylor, J. M. (2012) · Seminars in Liver Disease · doi:10.1055/s-0032-1323623 · Cited by 76
Bijsmans, I. T. G. W., Bouwmeester, R. A. M., Geyer, J., Faber, K. N., & van de Graaf, S. F. J. (2011) · Biochemical Journal · doi:10.1042/bj20111234 · Cited by 64
Wang, X., Hu, W., Zhang, T., Mao, Y., Liu, N., & Wang, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.007 · Cited by 60
Sureau, C., Fournier‐Wirth, C., & Maurel, P. (2003) · Journal of Virology · doi:10.1128/jvi.77.9.5519-5523.2003 · Cited by 52
van der Velden, L. M., Golynskiy, M. V., Bijsmans, I. T. G. W., van Mil, S. W. C., Klomp, L. W. J., Merkx, M., & van de Graaf, S. F. J. (2012) · Hepatology · doi:10.1002/hep.26012 · Cited by 48
Differential effects of cyclosporin a on the transport of bile acids by human hepatocytes
Azer, S. A., & Stacey, N. H. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90489-j · Cited by 46
Verrier, E. R., Colpitts, C. C., Bach, C., Heydmann, L., Zona, L., Xiao, F., Thumann, C., Crouchet, É., Gaudin, R., Sureau, C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.084 · Cited by 43
Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
Dong, Z., Ekins, S., & Polli, J. E. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.09.005 · Cited by 36
A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide
Dong, Z., Ekins, S., & Polli, J. E. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.022 · Cited by 28
Greupink, R., Nabuurs, S. B., Zarzycka, B. A., Verweij, V. G. M., Monshouwer, M., Huisman, M. T., & Rüssel, F. G. M. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs188 · Cited by 28
He, Z., Yan, L., Yong, Z., Dong, Z., Dong, H., & Gong, Z. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.003 · Cited by 24
Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers
Rust, C., Bauchmuller, K., Bernt, C., Vennegeerts, T., Fickert, P., Fuchsbichler, A., & Beuers, U. (2006) · Gut · doi:10.1136/gut.2005.077461 · Cited by 20
Flagged first, then by citations
Cited by
Sorted by citations
Animal models to study bile acid metabolism
Li, J., & Dawson, P. A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.011 · Cited by 269
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Hepatitis B Virus Entry into Cells
Herrscher, C., Roingeard, P., & Blanchard, E. (2020) · Cells · doi:10.3390/cells9061486 · Cited by 163
Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development
Hu, J., Lin, Y., Chen, P., Watashi, K., & Wakita, T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.093 · Cited by 127
Böhm, R., Bulin, C., Waetzig, V., Cascorbi, I., Klein, H., & Herdegen, T. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14868 · Cited by 96
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections
Tu, T., & Urban, S. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.04.004 · Cited by 68
Yang, L., Liu, F., Tong, X., Hoffmann, D. E., Zuo, J., & Lu, M. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00337 · Cited by 66
Sodium + /taurocholate cotransporting polypeptide as target therapy for liver fibrosis
Salhab, A., Amer, J., Lu, Y., & Safadi, R. (2021) · Gut · doi:10.1136/gutjnl-2020-323345 · Cited by 60
Peptides to combat viral infectious diseases
Al-Azzam, S., Ding, Y., Liu, J., Pandya, P., Ting, J. P., & Afshar, S. (2020) · Peptides · doi:10.1016/j.peptides.2020.170402 · Cited by 57
Yan, Y., Allweiss, L., Yang, D., Kang, J., Wang, J., Qian, X., Zhang, T., Liu, H., Wang, L., Liu, S., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1625728 · Cited by 59
Fukano, K., Tsukuda, S., Oshima, M., Suzuki, R., Aizaki, H., Ohki, M., Park, S., Muramatsu, M., Wakita, T., Sureau, C., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03257 · Cited by 57
In Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach
Tabernilla, A., Rodrigues, B. D. S., Pieters, A., Caufriez, A., Leroy, K., Campenhout, R. V., Cooreman, A., Gomes, A. R., Arnesdotter, E., Gijbels, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095038 · Cited by 54
Chronic hepatitis delta: A state-of-the-art review and new therapies
Gilman, C. A., Heller, T., & Koh, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i32.4580 · Cited by 47
Recent Advances in Hepatitis B Treatment
Prifti, G., Moianos, D., Giannakopoulou, E., Pardali, V., Tavis, J. E., & Zoidis, G. (2021) · Pharmaceuticals · doi:10.3390/ph14050417 · Cited by 50
Mechanistic insights into the inhibition of NTCP by myrcludex B
Donkers, J. M., Appelman, M. D., & van de Graaf, S. F. J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.006 · Cited by 42
Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles
Zhang, B., Kuipers, F., de Boer, J. F., & Kuivenhoven, J. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010004 · Cited by 43
AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate
Delijewski, M., & Haneczok, J. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100077 · Cited by 41
Kirstgen, M., Lowjaga, K. A. A. T., Müller, S. F., Goldmann, N., Lehmann, F., Alakurtti, S., Yli‐Kauhaluoma, J. T., Glebe, D., & Geyer, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-78618-2 · Cited by 37
Eller, C., Heydmann, L., Colpitts, C. C., Verrier, E. R., Schuster, C., & Baumert, T. F. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2892-y · Cited by 36
Chronic Hepatitis B Infection: New Approaches towards Cure
Ogunnaike, M., Das, S., Raut, S. S., Sultana, A., Nayan, M. U., Ganesan, M., Edagwa, B., Osna, N. A., & Poluektova, L. Y. (2023) · Biomolecules · doi:10.3390/biom13081208 · Cited by 33
Ni, Y., Zhang, Z., Engelskircher, L., Verch, G., Tu, T., Lempp, F. A., & Urban, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-46493-1 · Cited by 31
Concept of Viral Inhibitors via NTCP
Fukano, K., Tsukuda, S., Watashi, K., & Wakita, T. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676804 · Cited by 27
Innovative HBV Animal Models Based on the Entry Receptor NTCP
Wettengel, J. M., & Burwitz, B. J. (2020) · Viruses · doi:10.3390/v12080828 · Cited by 23
Zakrzewicz, D., & Geyer, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010196 · Cited by 23
Xiao, Y., Liu, C., Tang, W., Zhang, H., & Chen, X. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02638 · Cited by 23
Zhou, Q., Zhang, Q., Wang, K., Huang, T. H., Deng, S., Wang, Y., & Cheng, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106181 · Cited by 22
Nkongolo, S., Nußbaum, L., Lempp, F. A., Wodrich, H., Urban, S., & Ni, Y. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.04.009 · Cited by 21
Molecular mechanisms of Na+-driven bile acid transport in human NTCP
Lu, X., & Huang, J. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.03.033 · Cited by 20
Watashi, K., Shionoya, K., Kobayashi, C., & Morita, T. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01121-2 · Cited by 19
Chen, S., Zhang, L., Chen, Y., & Fu, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01097 · Cited by 18
Bile acid–microbiota crosstalk in hepatitis B virus infection
Wang, J., Xu, H., Liu, Z., Cao, Y., Chen, S., Hou, R., Zhou, Y., & Wang, Y. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16604 · Cited by 19
Maravelia, P., Frelin, L., Ni, Y., Pérez, N. C., Ahlén, G., Jagya, N., Verch, G., Verhoye, L., Pater, L. V., Johansson, M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa036 · Cited by 17
Qu, B., Nebioglu, F., Leuthold, M. M., Ni, Y., Mutz, P., Beneke, J., Erfle, H., Vondran, F. W. R., Bartenschlager, R. F. W., & Urban, S. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100551 · Cited by 15
Zhang, Z., Zhang, Q., Zhang, Y., Lou, Y., Ge, L., Zhang, W., Zhang, W., Song, F., & Huang, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115956 · Cited by 16
Yu, Y., Li, S., & Liang, W. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0137-7 · Cited by 13
Ivachtchenko, A. V., Mitkin, O. D., Kravchenko, D. V., Kovalenko, S. М., Shishkina, S. V., Bunyatyan, N. D., Konovalova, I. S., Геннадиевна, Д. И., Ivanov, V. V., & Langer, T. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02738 · Cited by 13
Tenge, V. R., Murakami, K., Salmen, W., Lin, S., Crawford, S. E., Neill, F. H., Prasad, B. V. V., Atmar, R. L., & Estes, M. K. (2021) · Viruses · doi:10.3390/v13060998 · Cited by 13
Tremmel, R., Nies, A. T., van Eijck, B. A. C., Handin, N., Haag, M., Winter, S., Büttner, F., Kölz, C., Klein, F., Mazzola, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137468 · Cited by 13
Zhao, S., Zhen, Y., Fu, L., Gao, F., Zhou, X., Huang, S., & Zhang, L. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126623 · Cited by 13
Novel mechanistic insights – A brand new Era for anti-HBV drugs
Lyu, W., Qin, H., Li, Q., Lu, D., Shi, C., Zhao, K., Zhang, S., Yu, R., Zhang, H., Zhou, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116854 · Cited by 12
Yang, J., König, A., Park, S., Jo, E., Sung, P. S., Yoon, S. K., Žusinaite, E., Kainov, D. E., Shum, D., & Windisch, M. P. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100296 · Cited by 11
Nkongolo, S., Hollnberger, J., & Urban, S. (2022) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-022-03486-2 · Cited by 12
ATP5B Is an Essential Factor for Hepatitis B Virus Entry
Ueda, K., & Suwanmanee, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179570 · Cited by 12
Wu, M., Huang, Y., & Hsiao, J. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01373-y · Cited by 12
Sandmann, L., Berg, T., Deterding, K., Fischer, N., Hinrichsen, H. M., Petersen, J., Tacke, F., Cornberg, M., & Collaborators (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2181-3046 · Cited by 11
Appelman, M. D., Robin, M. J. D., Vogels, E. W. M., Wolzak, C., Vos, W. G., Vos, H. R., van Es, R. M., Burgering, B. M. T., & van de Graaf, S. F. J. (2020) · Cells · doi:10.3390/cells9040986 · Cited by 11
Assessment of Statin Interactions With the Human NTCP Transporter Using a Novel Fluorescence Assay
Wang, Y., Wilkerson, M. D., Li, J., Zhang, W., Owens, A., Wright, S. E., & Hidalgo, I. J. (2020) · International Journal of Toxicology · doi:10.1177/1091581820953066 · Cited by 10
Aoki‐Utsubo, C., Indrasetiawan, P., Fukano, K., Muramatsu, M., Artanti, N., Hanafi, M., Hotta, H., & Kameoka, M. (2023) · Microbiology and Immunology · doi:10.1111/1348-0421.13064 · Cited by 10
Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro
Saran, C., Ho, H. S. S., Honkakoski, P., & Brouwer, K. L. R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147495 · Cited by 10
Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors
Kirstgen, M., Lowjaga, K. A. A. T., Müller, S. F., Goldmann, N., Lehmann, F., Glebe, D., Baringhaus, K. H., & Geyer, J. (2021) · Viruses · doi:10.3390/v13040666 · Cited by 10
Hepatitis Delta Enters a New Therapeutic Era
Soriano, V., & Aguilera, A. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix658 · Cited by 9
Xiang, H., Chen, Y., Zhang, J., Zhang, J. C., Pan, D., Liu, B., & Ouyang, L. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.017 · Cited by 9
Ren, H., Wang, J., Tang, H., Qian, X., Xia, B., Luo, Z., Xu, Z., Qi, Z., & Zhao, P. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105737 · Cited by 7
Sandmann, L., Berg, T., Deterding, K., Fischer, N., Hinrichsen, H. M., Petersen, J., Tacke, F., Cornberg, M., & Collaborators (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2181-3345 · Cited by 7
“Similarly, it has been shown in vitro that other drugs can also inhibit NTCP [88 – 90], so concomitant use (e.g., sulfasalazine, irbesar-tan, ezetimibe, ritonavir, and ciclosporin A) is not recommended [39].”
BackgroundErgosterol peroxide blocks HDV infection as a novel entry inhibitor by targeting human NTCP receptor
Chiou, W.-C., Lyu, Y.-S., Hsia, T.-L., Chen, J., Lin, L., Chang, M., Hsu, M.-S., & Huang, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116077 · Cited by 7
Chen, Y., Duan, M., Wang, X., Xu, J., Tian, S., Xu, X., Duan, A., Mahal, A., Zhu, Y., & Zhu, Q. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107385 · Cited by 7
Zhao, X., Iqbal, W., Sun, P., & Zhou, X. (2021) · Livers · doi:10.3390/livers1040019 · Cited by 8
Oligomerization of the HBV/HDV functional receptor NTCP expressed in Sf9 insect cell
Qin, T., Wang, Y., Nie, J., Yu, L., & Zeng, S. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130224 · Cited by 6
Zehnder, B., Urban, S., & Tu, T. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3986 · Cited by 6
Elucidation of host-virus surfaceome interactions using spatial proteotyping
Wendt, F., Milani, E. S., & Wollscheid, B. (2021) · Advances in virus research · doi:10.1016/bs.aivir.2021.03.002 · Cited by 3
Khojali, I. O., & Mohammed, M. Y. (2023) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2023.15.1.0111 · Cited by 5
A new hepatoma cell line exhibiting high susceptibility to hepatitis B virus infection
Ueda, Y., Wei-lin, G., Dansako, H., Nishitsuji, H., Satoh, S., Shimotohno, K., & Kato, N. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.126 · Cited by 4
Billo, V., Neelen, C., Wannowius, M., Neubauer, A., Fühler, B., Hagos, Y., & Geyer, J. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100910 · Cited by 4
Hintersteininger, M., Schwarz, M., Schwabl, P., Hartl, L., Balcar, L., Hofer, B., Kramer, G., Sebesta, C., Thöne, P., Attalla, P., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70675 · Cited by 3
Hausmann, S., Geiser, J., & Valentini, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115194 · Cited by 2
Kunz, S. N., Soppa, L., Leidolf, R., Neubauer, A., Lütteke, T., Glebe, D., & Geyer, J. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100069 · Cited by 4
Direct-acting antivirals and viral RNA targeting for hepatitis B cure
French, J., LOCARNINI, S. A., & Zoulim, F. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000622 · Cited by 4
Ivachtchenko, A. V., Kovalenko, S. М., Kravchenko, D. V., Mitkin, O. D., Ivanov, V. V., & Langer, T. (2019) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989019015986 · Cited by 3
Kovalenko, S. М., Drushlyak, O. G., Shishkina, S. V., Konovalova, I. S., Mariutsa, I. O., Bunyatyan, N. D., Kravchenko, D. V., Ivanov, V. V., Ivachtchenko, A. V., & Langer, T. (2020) · Molecules · doi:10.3390/molecules25184238 · Cited by 3
Zeng, Y., Li, Z., Shang, J., & Kang, Y. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3681 · Cited by 2
Mohammed, M. Y., Khaier, M. A. M., Agabna, N., & Shaddad, S. A. (2022) · Saudi Journal of Biomedical Research · doi:10.36348/sjbr.2022.v07i11.003 · Cited by 2
Ivachtchenko, A. V., Mitkin, O. D., Kravchenko, D. V., Kovalenko, S. М., Shishkina, S. V., Bunyatyan, N. D., Konovalova, I. S., Ivanov, V. V., Konovalova, O. D., & Langer, T. (2019) · Crystals · doi:10.3390/cryst9120644 · Cited by 2
Major Advances in Hepatitis C Treatment but Not Hepatitis B
Fong, I. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-36966-8_5 · Cited by 2
Chicago Sky Blue diazo-dye release from poly(methyl methacrylate) (PMMA) electrospun nanofibers
Dias, Y. J., Sinha‐Ray, S., Pourdeyhimi, B., & Yarin, A. L. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.117771 · Cited by 2
Pathophysiologic Basis for Alternative Therapies for Cholestasis
Fuchs, C. D., Halilbasic, E., & Trauner, M. A. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch30 · Cited by 2
NTCP ubiquitination enables HBV infection
Appelman, M. D., Nguyen, T.-A., Oswald, A., Lucko, A., Paulusma, C. C., Protzer, U., & van de Graaf, S. F. J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101534 · Cited by 1
Xie, Q., Liu, Q., Zheng, X., Fu, L., Aly, H. H., & Liu, B. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104664 · Cited by 1
Shionoya, K., Kobayashi, C., Matsuzawa, K., & Watashi, K. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106418 · Cited by 1
Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model
Rusnak, J., Delcheva, V., Theile, D., Blank, A., Frey, N., & Preusch, M. R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349211 · Cited by 1
Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV
Sakiani, S., Asif, B., Yang, A. H., & Koh, C. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00550-w · Cited by 1
Entry Inhibitors of Hepatitis B and D Viruses
Yang, Y., & Xie, Y. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-8702-0_12 · Cited by 1
Ayewoh, E. N., & Swaan, P. W. (2022) · Wiley eBooks · doi:10.1002/9781119739883.ch9 · Cited by 2
Zhou, T., ZHANG, Y., ZHANG, J., Xie, C., Zhai, Z., & Wu, X. (2022) · Biocell · doi:10.32604/biocell.2022.021290
Novel hepatocyte-like liver organoids recapitulate crucial mature hepatic functionsPreprint
Ardisasmita, A. I., Joore, I. P., Levy, N., Myszczyszyn, A., Marsee, A., Sinnige, T. L., Ruiter, J. P. N., Ferdinandusse, S., Dudaryeva, O. Y., Gruber, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620824
A genome-wide gain-of-function screen identifies CDKN2C as HBV host factor
Eller, C. (2019) · theses.fr (ABES) · doi:10.70675/e50bdd53z0e37z43a3zb166z8fa8ed7204d7
Szabó, E., Telbisz, Á., Erdei, Z., Farkas, K., Homolya, L., Sarkadi, B., & Apáti, Á. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100157 · Cited by 1
BindingDB Entry 50023470: Novel mechanistic insights - A brand new Era for anti-HBV drugs.
BindingDB (2026) · UC San Diego · doi:10.7270/q2mk6jtq
Metadata
- Authors
- Donkers, J. M., Zehnder, B., van Westen, G. J. P., Kwakkenbos, M. J., IJzerman, A. P., Oude Elferink, R. P. J., Beuers, U., Urban, S., & van de Graaf, S. F. J.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Hospital Heidelberg (DE)
- AIMM Therapeutics (Netherlands) (NL)
- Leiden University (NL)
- Heidelberg University (DE)
- ORCID
- Venue
- Scientific Reports
- Published
- 2017-11-10
- Volume
- 7
- Issue
- 1
- Pages
- 15307-15307
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5681660
- OpenAlex
- W2767255832
- Cited by
- 90
- References
- 47
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 6 · 2023: 9 · 2022: 13 · 2021: 14 · 2020: 15 · 2019: 17 · 2018: 6 · 2017: 1
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- normal tissue complication probability, sodium taurocholate cotransporting polypeptide, SLC10A1, hepatitis B virus, hepatitis delta virus, viral entry inhibition, bile acid transport, Myrcludex B, rosiglitazone, zafirlukast, triac, sulfasalazine, ASBT, drug repurposing
- MeSH terms
- Rosiglitazone, Animals, Antiviral Agents, Hepatitis Delta Virus, Hepatitis D, Dogs, Hepatitis B, Hepatitis B virus, Humans, Indoles, Sulfasalazine, Sulfonamides, Tosyl Compounds, Triiodothyronine, Trypan Blue, Symporters, Organic Anion Transporters, Sodium-Dependent, Phenylcarbamates, Virus Internalization, Lipopeptides, Madin Darby Canine Kidney Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
